Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme

INTRODUCTION: Dapagliflozin is an orally active inhibitor of sodium-glucose co-transporter 2 (SGLT2) that is indicated for use in adults with type 1 diabetes (T1DM) (with a body mass index (BMI) of at least 27 kg/m(2) in Europe, no such BMI limit in Japan), when insulin alone does not provide adequa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Jason, Danne, Thomas, Beresford-Hulme, Lee, Bennet, Hayley, Tank, Amarjeet, Edmonds, Christopher, Thorén, Fredrik, Scheerer, Markus Florian, McEwan, Phil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192983/
https://www.ncbi.nlm.nih.gov/pubmed/32274678
http://dx.doi.org/10.1007/s13300-020-00807-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192983/
https://www.ncbi.nlm.nih.gov/pubmed/32274678
http://dx.doi.org/10.1007/s13300-020-00807-z

Ejemplares similares